Drug Patents owned by Bdsi

1. Drug name - BELBUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief Dec, 2032

(10 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery of buprenorphine

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.075MG BASE FILM;BUCCAL Prescription
EQ 0.15MG BASE FILM;BUCCAL Prescription
EQ 0.3MG BASE FILM;BUCCAL Prescription
EQ 0.45MG BASE FILM;BUCCAL Prescription
EQ 0.6MG BASE FILM;BUCCAL Prescription
EQ 0.75MG BASE FILM;BUCCAL Prescription
EQ 0.9MG BASE FILM;BUCCAL Prescription

2. Drug name - BUNAVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device Apr, 2035

(12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Treatment of opioid dependence; Maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

3. Drug name - ELYXYB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9795620 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US9949990 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US10799517 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US10722456 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US10376527 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

US9572819 BDSI Oral composition of celecoxib for treatment of pain May, 2036

(13 years from now)

Drugs and Companies using CELECOXIB ingredient

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/ML SOLUTION;ORAL Prescription

4. Drug name - ONSOLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597288 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: Management of breakthrough pain in patients with cancer

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.2MG BASE FILM;BUCCAL Discontinued
EQ 0.4MG BASE FILM;BUCCAL Discontinued
EQ 0.6MG BASE FILM;BUCCAL Discontinued
EQ 0.8MG BASE FILM;BUCCAL Discontinued
EQ 1.2MG BASE FILM;BUCCAL Discontinued

5. Drug name - SYMPROIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46375 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Oct, 2026

(4 years from now)

USRE46365 BDSI 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Jan, 2028

(5 years from now)

US9108975 BDSI Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Nov, 2031

(9 years from now)

US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(10 years from now)

CN101228172A BDSI 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative
May, 2026

(3 years from now)

CN101228172B BDSI 6, 7-Unsaturated -7-Carbamoyl Substituted Morphinan Derivative.
May, 2026

(3 years from now)

CN103298819B BDSI 6, 7-Unsaturated -7 - Carbamoyl Morphinan Derivative Crystal And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105131003A BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

CN105131003B BDSI 6, 7-Unsaturated -7 - Carbamoyl-Morphinan Derivative Crystal And Its Preparation Method
Nov, 2031

(9 years from now)

CN103298819A BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

IN200705325P4 BDSI 6, 7-Unsaturated-7-Carbamoyl-Substituted Morphinan Derivative
May, 2026

(3 years from now)

IN264360B BDSI 6,7-Unsaturated-7-Carbamoyl-Substituted Morphinan Derivative
May, 2026

(3 years from now)

IN315783B BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP1889848A1 BDSI 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative
May, 2026

(3 years from now)

EP1889848B1 BDSI 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative
May, 2026

(3 years from now)

EP1889848A4 BDSI 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative
May, 2026

(3 years from now)

EP1889848B8 BDSI 6,7-Unsaturated-7-Carbamoyl Substituted Morphinan Derivative
May, 2026

(3 years from now)

EP3560929A2 BDSI Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate
Nov, 2031

(9 years from now)

EP3560929A3 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP2639234B1 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP2639234A1 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP2639234A4 BDSI Crystalline 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Method For Producing Same
Nov, 2031

(9 years from now)

EP3560929B1 BDSI Process For Preparing 6,7-Unsaturated-7-Carbamoyl Morphinane Derivative, And Intermediate
Nov, 2031

(9 years from now)

EP2851075B1 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

EP2851075A1 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

EP2851075A4 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.2MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.